



**Great
Debates
& Updates**

Gastrointestinal Malignancies



**Now Offering
2 Locations**

New York, NY
March 29–30, 2019

Chicago, IL
September 13–14, 2019

Where Debate
& Discussion
Translate to
Breakthroughs

Greatdebatesingastro.com

AN **IMEDEX** EVENT
AN HMP COMPANY

2 Days of Unparalleled Education.

Interactive Format.

Practical Implications.

Join us for a unique educational experience. In this 2-day debate-style series, nationally recognized thought leaders take opposing sides on clinical—and sometimes controversial—topics currently disrupting the practice of gastrointestinal oncology.

This one-of-a-kind gastrointestinal cancer conference provides a substantial curriculum covering the broad continuum of:

- **Colorectal Cancers**
 - **Immunotherapy**
 - **Emerging Concepts and Therapies in GI**
 - **Rare Tumors**
 - **Upper GI Cancers**
 - **Pancreatic Cancers**
 - **Hepatobiliary Cancers**
 - **Colorectal Cancers**
-

GREAT DEBATES & UPDATES IN
GASTROINTESTINAL MALIGNANCIES



Endorsed by



Exhibits

This conference series offers several support opportunities that are designed to increase your companies' recognition and the opportunity to showcase your products and services to this audience of oncology professionals.

Interested in Exhibiting?
(678) 242-0719
exhibits@imedex.com

Meet the Chairs



Axel Grothey, MD
West Cancer Center
Memphis, Tennessee



David H. Ilson, MD, PhD
Memorial Sloan Kettering
Cancer Center
New York, New York

Faculty

Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering
Cancer Center
New York, New York

Tanios Bekaii-Saab, MD, FACP
Mayo Clinic
Phoenix, Arizona

Michael A. Choti, MD
Banner MD Anderson
Cancer Center
Gilbert, Arizona

Christopher H. Crane, MD
Memorial Sloan Kettering
Cancer Center
New York, New York

Cathy Eng, MD
MD Anderson Cancer Center
University of Texas
Houston, Texas

**José G. Guillem, MD, MPH,
FACS, FASCRS**
Memorial Sloan Kettering
Cancer Center
New York, New York

Howard Hochster, MD
Rutgers Cancer Institute
of New Jersey
New Brunswick, New Jersey

Scott Kopetz, MD, PhD
MD Anderson Cancer Center
University of Texas
Houston, Texas

Eileen O'Reilly, MD
Memorial Sloan Kettering
Cancer Center
New York, New York

Neil H. Segal, MD, PhD
Memorial Sloan Kettering
Cancer Center
New York, New York

Zsafia K. Stadler, MD
Memorial Sloan Kettering
Cancer Center
New York, New York

Jonathan Strosberg, MD
Moffitt Cancer Center
Tampa, Florida

Eric Van Cutsem, MD PhD
University Hospital
Gasthuisberg
Leuven, Belgium

*For full faculty list, please visit the website.

NEW YORK: MAR 29–30, 2019
CHICAGO: SEPT 13–14, 2019

GREATDEBATESINGASTRO.COM

DAY 1 | Friday

Session I: Colorectal Cancers I

- 08:00 AM Welcome and Introduction
- 08:10 AM Pre-Session Survey Using ARRAY
- 08:20 AM Update: Novel Agents and Targets in CRC
- 08:40 AM Debate: HIPEC or Not for Small Volume Carcinomatosis, CRC?
- 09:00 AM Debate: Should Anyone Get 6 Months of Adjuvant Chemotherapy in Colon Cancer: Yes or No?
- 09:20 AM Post-Session Survey Using ARRAY
- 09:30 AM Expert Panel Discussion
- 09:45 AM Break

Session II: Colorectal Cancers II

- 10:05 AM Pre-Session Survey Using ARRAY
- 10:15 AM Update on the Role of Non-Surgical Management in Rectal Cancer
- 10:35 AM Debate: First Line BRAF V600E: Targeted Triplet vs FOLFOXIRI/Bev?
- 10:55 AM Debate: MSI High Colon Cancer: Upfront Chemo or IT?
- 11:15 AM Update: What is the Optimal Dose Fractionation Schedule of RT in Rectal Cancer?
- 11:35 AM Post-Session Survey Using ARRAY
- 11:45 AM Expert Panel Discussion
- 12:00 PM Lunch

Session III: Targeted Approaches

- 1:30 PM Pre-Session Survey Using ARRAY
- 1:40 PM Update: Enhanced Immunotherapy Approaches and Novel IT Targets in GI Cancers
- 2:00 PM Debate: TNT vs Conventional Preop ChemoRT in Rectal Cancer
- 2:20 PM Update: Novel Drugs and Targets in GI Malignancies Beyond Immunotherapy
- 2:40 PM Update: Locoregional Treatment Approaches: When to Use and When Not
- 3:00 PM Debate: Ipi/Nivo vs Nivo or Pembro Alone in MSI High Colorectal Cancer
- 3:20 PM Break

Session IV: Gastrointestinal Malignancies: Emerging Concepts and Therapies

- 3:40 PM Pre-Session Survey Using ARRAY
- 3:50 PM Update: ASA Therapy for GI Cancers and Cancer Prevention
- 4:10 PM Update: Circulating Tumor DNA: Emerging Role in Adjuvant and Advanced Disease Therapy
- 4:30 PM Post-Session Survey Using ARRAY
- 4:50 PM Expert Panel Discussion
- 5:00 PM Adjourn

DAY 2 | Saturday

The scientific agenda for the September event will include highlights from groundbreaking research released at other scientific conferences. Please visit the website for full agenda details.

Session V: Rare Tumors

- 08:00 AM Welcome and Introduction
- 08:10 AM Pre-Session Survey Using ARRAY
- 08:20 AM Debate: Squamous Cancer of the Esophagus Treated With Definitive RT: Higher RT Dose Needed vs Standard 5040 cGy Should Be Given
- 08:40 AM Debate: Optimal Second Line Therapy in pNET is Cape/Tem versus PRRT?
- 09:00 AM Update: New Treatment Options in Rare Tumors
- 09:20 AM Post-Session Survey Using ARRAY
- 09:30 AM Expert Panel Discussion
- 09:45 AM Break

Session VI: Upper GI Cancers

- 10:05 AM Pre-Session Survey Using ARRAY
- 10:15 AM Update: Update in Adjuvant Therapy Options for Esophagogastric Cancer
- 10:35 AM Debate: Second Line Therapy: Paclitaxel Ramucirumab or Pembro?
- 10:55 AM Debate: Late Line Therapy: TAS102 or Pembro/Nivo?
- 11:15 AM Post-Session Survey Using ARRAY
- 11:25 AM Expert Panel Discussion
- 11:40 AM Lunch

Session VII: Pancreatic Cancer

- 1:20 PM Pre-Session Survey Using ARRAY
- 1:30 PM Update: New Treatment Options in Pancreatic Cancer
- 1:50 PM Debate: SBRT or IMRT in Radiation-Based Therapy for Pancreatic Cancer
- 2:10 PM Debate: Preoperative Chemo/Chemoradiotherapy or Adjuvant FOLFIRINOX for Pancreatic Cancer?
- 2:30 PM Post-Session Survey Using ARRAY
- 2:40 PM Expert Panel Discussion
- 3:00 PM Break

Session VIII: Hepatobiliary Cancers

- 3:20 PM Pre-Session Survey Using ARRAY
- 3:30 PM Update: Novel Agents and Targets in Biliary Cancer
- 3:50 PM Debate: Optimal Second Line Therapy for HCC is a TKI or Ram/Is Cabozantinib?
- 4:10 PM Update: Optimal Sequencing of Agents in HCC and Novel Agents and Targets
- 4:30 PM Post-Session Survey Using ARRAY
- 4:40 PM Expert Panel Discussion
- 5:00 PM Closing Notes and Adjourn

Continuing Education

Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statements

Physicians: Imedex, LLC designates this live educational activity for a maximum of 13.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC): Successful completion of this CME activity enables a participant to earn up to 13.0 MOC points toward the American Board of Internal Medicine's (ABIM) MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points. The deadline to claim MOC points is May 31, 2019 for New York and November 14, 2019 for Chicago. ABIM Diplomates will be asked to provide their identification number and DOB.

Nursing: This continuing nursing education activity awards 13.0 contact hours. This activity will also award pharmacotherapeutic contact hours; however, the final assignment of these contact hours will be announced once all content has been approved.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 13.0 contact hours.

Pharmacy: This live, knowledge-based activity has been approved for a maximum of 13.0 contact hours (1.3 CEUs).

(NY Universal Activity Number: JA0006201-9999-19-003-L01-P. Deadline to claim credit: 3/31/2019)

(CHI Universal Activity Number: JA0006201-9999-19-005-L01-P. Deadline to claim credit: 11/14/2019)

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is 60 days from the end of the activity (see above). Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

Physician Assistants: NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 13.0 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.



Who Should Attend

These live educational activities are designed to meet the educational needs of those who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.

- Gastroenterologists
- Medical Oncologists
- Physicians
- Physician Assistants
- Physicians-in-Training
- Oncology Nurses
- Pharmacists

Group Discounts available for attendees from the same practice!

Educational Grant Support

Several options are available to companies interested in supporting this conference with an educational grant. For more information, please contact Dan Alba, Senior Director, Educational Strategy, Oncology Learning Network at d.alba@imedex.com.

Exhibition Support

Several options are available to companies who wish to exhibit at this meeting. For more information, please contact Stacy S. Brandau, Director, Global Business Development at s.brandau@imedex.com.

More Locations, Education, and Value



New York Marriott Marquis
1535 Broadway
New York, New York 10036
Tel: (212) 398-1900

Special Room Rate:
\$289.00
per night, plus tax.



Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois 60605
Tel: (312) 922-4400

Special Room Rate:
\$199.00
per night, plus tax.



Ways to Register

Online: Greatdebatesingastro.com
Phone: (800) 233-0957 | **International:** (678) 242-0906

Rates	Physicians PhDs Pharmacists	Nurse Practitioners Physician Assistants	Nurses Residents Students	Pharmaceutical Industry
Early	\$279.00	\$169.00	\$89.00	\$499.00
Regular	\$329.00	\$199.00	\$99.00	

For assistance, please contact registration@imedex.com.

To reserve the best rates, sign-up before:

New York: March 1, 2019
Chicago: August 16, 2019

GREATDEBATESINGASTRO.COM

Enroll in the **Great Debates & Updates Value Package** and save by signing up for multiple locations at once!



Great
Debates
& Updates

Gastrointestinal
Malignancies



AN HMP COMPANY

11675 Rainwater Drive, Suite 600, Alpharetta, GA 30009, USA

Where Debate
& Discussion
Translate to
Breakthroughs

New York, NY

March 29–30, 2019

Chicago, IL

September 13–14, 2019

Reserve your seat today:
Greatdebatesingastro.com